T-cell Or Derivative Patents (Class 435/372.3)
  • Patent number: 10378070
    Abstract: Provided is a method for continuously visualizing and accurately determining a living cellular state per se. Disclosed are: a vector comprising 5?- and 3?-end nucleic acid sequences for integration and a reporter gene sequence positioned between the 5?- and 3?-end nucleic acid sequences for integration; a gene introduction agent comprising a first vector and a second vector; a cell comprising the vector or the agent; and a method for determining a cellular state by using the cell.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 13, 2019
    Assignee: Kyoto University
    Inventors: Hirohide Saito, Hideyuki Nakanishi
  • Patent number: 10335472
    Abstract: The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: July 2, 2019
    Assignee: Cadila Pharmaceuticals Ltd.
    Inventors: Bakulesh Mafatlal Khamar, Nirav Manojkumar Desai, Chandreshwar Prasad Shukla, Avani Devenbhai Darji, Indravadan Ambalal Modi
  • Patent number: 10040846
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: August 7, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Patent number: 9856322
    Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: January 2, 2018
    Assignee: St Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, Chihaya Imai
  • Patent number: 9834608
    Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: December 5, 2017
    Assignee: The Regents of the University of California
    Inventors: Wendell A. Lim, Leonardo Morsut, Kole T. Roybal
  • Patent number: 9518989
    Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: December 13, 2016
    Assignee: Texas Tech University System
    Inventor: Maurizio Chiriva-Internati
  • Patent number: 9499629
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: November 22, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9345691
    Abstract: Compositions and methods are provided, comprising at least one beta-lactam compound selected from the group consisting of cefuroxime, a penicillin, ceftriaxone, clavulanic acid, 6-aminopenicillanic acid (6-APA) and tazobactam, for enhancing T cell mediated immune responses in a subject, such as anti-tumor and anti-viral immune responses.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: May 24, 2016
    Assignee: STEM CELL MEDICINE LTD.
    Inventors: Irun R. Cohen, Felix Mor
  • Patent number: 9192628
    Abstract: Disclosed is a method for treating relapsing-remitting multiple sclerosis in a patient by administering to the patient autologous, ex vivo-expanded CD4+CD25+Foxp3+CD127low T reg cells when the patient is in remission. Also disclosed is a method of inhibiting the activity of autoimmune, autologous cytotoxic T and B cells in a patient suffering from relapsing-remitting multiple sclerosis, comprising administering a therapeutically effective amount of autologous CD4+CD25+Foxp3+CD127low T reg cells to the patient.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: November 24, 2015
    Assignee: REGENEX LLC
    Inventors: Svetlana Nunevna Bykovskaia, Daria Dmitrievna Eliseeva, Igor Alekseevich Zavalishin
  • Patent number: 9181526
    Abstract: Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: November 10, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Bruce Blazar, Carl June, Wayne R. Godfrey, Richard G. Carroll, Bruce Levine, James L. Riley, Patricia Taylor
  • Patent number: 9101584
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9102761
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9102760
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20150132285
    Abstract: The present invention provides a method of making a proteinase-engineered cancer vaccine for treating a cancer patient, especially for cancer patient at advanced/metastatic stage. The cancer vaccine comprises dead cancer cells with unbroken plasma membrane wherein the extracellular proteins and extracellular portion of membrane proteins are cleaved by proteinase digestion. The cancer vaccine may be derived from cancer cell lines or patients' cancer cells. The present invention provides a method of treating a cancer patient by administrating an effective amount of the cancer vaccine to the patient. In a clinical trial with 35 cancer patients, the cancer vaccine therapy brings cancer-free lives (no detectable tumor, micro tumor or cancer cells after treatment) back to 40% of these patients. The cancer vaccine therapy for the first time brings the promise of cure to this deadly disease.
    Type: Application
    Filed: January 11, 2015
    Publication date: May 14, 2015
    Inventor: Yong Qian
  • Patent number: 9029139
    Abstract: Methods for generating and using omentum cells, and particularly stromal cells and/or omentum stem cells, in medical treatments such as tissue repair and regeneration to facilitate healing from traumatic injury to an abdominal organ, and immune modulation treatments such as suppression of immune responses and inflammation and prevention of tissue fibrosis. According to one aspect, a medical procedure is performed on a patient that involves harvesting omental tissue from the patient, and then transferring the omental tissue to an organ of the patient. At least a portion of the harvested omental tissue may be activated prior to transferring the omental tissue to the organ. Alternatively, the transferred omental tissue may comprise non-lymphoid cells isolated from the omentum tissue and obtained by homogenizing at least a portion of the harvested omental tissue.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: May 12, 2015
    Assignee: Loyola University of Chicago
    Inventors: Makio Iwashima, Robert Love, Rudolf Karl Braun, Perianna Sethupathi, Katherine Lathrop Knight
  • Publication number: 20150126410
    Abstract: The invention relates in a first embodiment to a method for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region, wherein said adenoviruses are generated in a production cell, the method comprising the steps of: (a) expressing in said production cell an adenoviral pIX polypeptide from a nucleic acid sequence encoding said adenoviral pIX polypeptide under the control of (i) at least a minimal endogenous pIX promoter and a heterologous promoter; or (ii) a heterologous promoter; and (b) expressing in said production cell the elements necessary for the production and assembly of said adenoviruses from corresponding coding sequences, thereby increasing the yield of said adenoviruses generated in said production cell in comparison to the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region generated in said production cell in the absence of said nucleic acid sequence encoding said adenoviral pIX polypeptide.
    Type: Application
    Filed: July 4, 2013
    Publication date: May 7, 2015
    Inventors: Christian Thirion, Zsolt Ruzsics
  • Publication number: 20150125477
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: November 3, 2014
    Publication date: May 7, 2015
    Inventors: Sabrina KUTTRUFF-COQUI, Toni WEINSCHENK, Jens FRITSCHE, Steffen WALTER, Norbert HILF, Oliver SCHOOR, Colette SONG, Harpreet SINGH
  • Patent number: 9023646
    Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1 ? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: May 5, 2015
    Assignee: Research Development Foundation
    Inventors: Didier Trono, Patrick Salmon
  • Publication number: 20150110757
    Abstract: Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and cells comprising polynucleotides encoding ZF-TFs or ZFNs and/or cells comprising ZF-TF or ZFNs are also provided.
    Type: Application
    Filed: September 24, 2014
    Publication date: April 23, 2015
    Inventors: Michael C. Holmes, Jeffrey C. Miller, Jianbin Wang
  • Publication number: 20150093822
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 8975070
    Abstract: The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: March 10, 2015
    Assignee: Takara Bio Inc.
    Inventors: Hiroaki Sagawa, Mitsuko Ideno, Ikunoshin Kato
  • Patent number: 8975071
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 10, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 8975069
    Abstract: A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: March 10, 2015
    Assignee: St. Vincent's Hospital Sydney Limited
    Inventors: Anthony Dominic Kelleher, John James Zaunders, Nabila Seddiki
  • Patent number: 8951796
    Abstract: The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: February 10, 2015
    Assignee: University of Southern California
    Inventors: Song Guo Zheng, David A. Horwitz, Juhua Wong
  • Patent number: 8951793
    Abstract: Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: February 10, 2015
    Assignee: The United States of America, as represented by The Secretary, Department of Health and Human Services
    Inventors: Dat Tran, Ethan M. Shevach
  • Patent number: 8951510
    Abstract: A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4143-151-specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: February 10, 2015
    Assignees: Mie University, Takara Bio Inc.
    Inventors: Hiroshi Shiku, Atsunori Hiasa, Satoshi Okumura, Hiroaki Naota, Yoshihiro Miyahara
  • Patent number: 8932854
    Abstract: The invention relates to a porous material for body fluid treatment for promoting lymphocyte proliferation in lymphocyte culture which contains a high-molecular compound having an angle of contact with water within the range of 40 to 98°, and a porous material for body fluid treatment which comprises activated carbon; and also relates to a treatment device wherein the porous material is used; a method for proliferating lymphocytes; a method for producing mammalian lymphocytes; a method for producing a pharmaceutical composition; an additive body fluid to be added to a culture medium on the occasion of lymphocyte culture; a method for treating a disease against which a therapeutic effect is produced by returning extracorporeally activated mammalian lymphocytes into the body; and a method of manufacturing the porous materials for body fluid treatment for promoting the lymphocyte proliferation in lymphocyte culture.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: January 13, 2015
    Assignee: Kaneka Corporation
    Inventors: Akira Kobayashi, Shinya Yoshida, Katsuo Noguchi
  • Patent number: 8920807
    Abstract: The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 30, 2014
    Assignees: The Regents of the University of California, The United States of America Represented by the Department of Veterans Affairs
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Steven M. Dubinett, Sherven Sharma, Upendra K. Kar
  • Patent number: 8921050
    Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: December 30, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
  • Publication number: 20140377240
    Abstract: Disclosed herein are methods and compositions for expanding T-regulatory cells (“Treg” cells), resulting in “conditioned Treg cells.” Also disclosed herein are methods and compositions useful for modulating an autoimmune reaction and for treating or ameliorating immune-related diseases, disorders and conditions using the conditioned Treg cells.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 25, 2014
    Applicant: Northeastern University
    Inventors: Michail Sitkovsky, Akio Ohta, Akiko Ohta
  • Patent number: 8916381
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 23, 2014
    Assignee: The Trustees of the University of Pennyslvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 8911993
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: December 16, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 8906682
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: December 9, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20140356398
    Abstract: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Application
    Filed: June 12, 2014
    Publication date: December 4, 2014
    Inventors: Stanley R. Riddell, Carolina Berger, Michael C. Jensen
  • Patent number: 8895264
    Abstract: Nucleases and methods of using these nucleases for modification of an HPRT locus and for increasing the frequency of gene modification at a targeted locus and clones and for generating animals.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: November 25, 2014
    Assignees: Sangamo BioSciences, Inc., The Regents of the University of California
    Inventors: Gregory J. Cost, Michael C. Holmes, Noriyuki Kasahara, Josee Laganiere, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Fyodor Urnov, Lei Zhang
  • Publication number: 20140315304
    Abstract: Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34+ hematopoietic cells, such as human CD34+ blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 23, 2014
    Applicant: Cellular Dynamics International, Inc.
    Inventors: Matthew BROWN, Elizabeth Rondon DOMINGUEZ, Randy LEARISH, Emile NUWAYSIR, Deepika RAJESH, Amanda MACK
  • Publication number: 20140310830
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 16, 2014
    Inventors: Feng ZHANG, Le CONG, Fei RAN
  • Publication number: 20140294784
    Abstract: Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Scott A. Waldman, Adam E. Snook, Michael S. Magee
  • Publication number: 20140295544
    Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventor: Khalid S. Abu KHABAR
  • Publication number: 20140294793
    Abstract: The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Inventors: Dan R. Littman, Sang-Won Kim
  • Patent number: 8846373
    Abstract: The present invention relates to new methods to promote sialylation of glycoconjugates, including recombinant glycoproteins, in glycoconjugate production systems. The invention relates to methods to promote efficient glycoconjugate sialylation in recombinant expression systems, by providing simpler and more economical ways to produce large intracellular pools of sialic acid precursors. The invention is directed to nucleic acids, vectors, and cells harboring vectors comprising nucleic acids encoding enzymes involved in the synthesis of sialic acid precursors, and cells harboring these nucleic acids in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins in bacterial, fungal, plant, and animal cell expression systems.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: September 30, 2014
    Assignee: The University of Wyoming
    Inventors: Christoph Geisler, Donald Jarvis
  • Patent number: 8840888
    Abstract: Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 23, 2014
    Assignee: Micromet AG
    Inventors: Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Baeuerle
  • Publication number: 20140274909
    Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a) an antigen binding domain of HA22, a transmembrane domain, and an intracellular T cell signaling domain; or b) an antigen binding domain of BL22, a transmembrane domain, and an intracellular T cell signaling domain comprising CD28 and/or CD137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 18, 2014
    Inventors: Rimas J. Orentas, Crystal L. Mackall, Ira H. Pastan
  • Patent number: 8828723
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: September 9, 2014
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Patent number: 8822647
    Abstract: Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13R?2 specific IL13-zetakine (IL13?), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: September 2, 2014
    Assignee: City of Hope
    Inventor: Michael Jensen
  • Publication number: 20140234943
    Abstract: The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 21, 2014
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Roberto Cattaneo, Vincent H.J. Leonard
  • Publication number: 20140219975
    Abstract: The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide that is associated with a negative signal and the second domain is a polypeptide that is associated with a positive signal. Thus, the invention encompasses switch receptors that are able to switch negative signals to positive signals for enhancement of an immune response.
    Type: Application
    Filed: July 27, 2012
    Publication date: August 7, 2014
    Inventors: Carl H. June, Yangbing Zhao
  • Publication number: 20140219978
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Application
    Filed: December 13, 2013
    Publication date: August 7, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • Patent number: 8796018
    Abstract: The invention relates to the use of nanopatterned surfaces. It also relates to a method for enriching or isolating cellular subpopulations. To create a simple, versatile and specific method for enriching or isolating cellular subpopulations from a complex mixture, the invention proposes the use of nanopatterned surfaces for isolating and enriching cellular subpopulations from a complex mixture.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 5, 2014
    Assignee: Leibniz-Institut fuer Neue Materialien Gemeinneutzige Gesellschaft mit beschraenkter Haftung
    Inventors: Michael Veith, Frank Narz
  • Publication number: 20140206620
    Abstract: The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Steven A. Rosenberg, Richard A. Morgan, Timothy L. Frankel